// App-Quantinova.ai

Abstract 11143 : Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials

Researchers

Presenter

  • Lawrence A Leiter

Principal Investigators

  • David G Kallend

  • Wolfgang Koenig

  • Ulf Landmesser

  • Kausik K Ray

  • Gregory G Schwartz

  • R S Wright

  • yanntong chiang

  • Lorena Garcia Conde Orozco

  • Frederick J Raal

Medical Centers

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Imperial Cntr for Cardiovascular Disease Prevention, Dept of Primary Care and Public Health, Imperial College London, London, United Kingdom

  • Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

  • Radiology, Univ of Colorado Sch of Medicine, Aurora, CO

  • Deutsches Herzzentrum München, Technische Universität München, DZHK (German Cntr for Cardiovascular Rsch), partner site Munich Heart Alliance, Munich, Germany

  • Div of Preventive Cardiology and Dept of Cardiology, Mayo Clinic, Rochester, MN

  • Li Ka Shing Knowledge Institute, St. Michaels Hospital and University of Toronto, Toronto, ON, Canada

  • DalCor Pharmaceuticals, Montreal, Canada

  • Novartis AG, Basel, Switzerland

  • Dept of Cardiology, Charité-Univ Medicine Berlin, Berlin Institute of Health (BIH), DZHK, partner site Berlin, Berlin, Germany

Locations

  • United States

  • United Kingdom

  • South Africa

  • Germany

  • Canada

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Body mass index

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03397121

  • NCT03399370

  • NCT03400800

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved